News BMS eyes filings for myeloma 'celmod' iberdomide Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.
Oncology The cancer community must seize the opportunity of the Natio... With the government’s National Cancer Plan due for publication this autumn, we have an opportunity to fundamentally improve how we deliver innovation.
News Roche's oral SERD comes good in 2nd-line breast cancer trial Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.
News FDA clears subcutaneous Keytruda in a boost to MSD MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.
Oncology Current and future standard of care in prostate cancer Despite recent advancements in the field of prostate cancer treatment, there remain distinct gaps in the current standard of care needing improvement.
News Imfinzi becomes first NHS drug for aggressive lung cancer AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.
News Roche, Viking, and Syntis showcase obesity drug candidates A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.